This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BMS-626529 prodrug, HIV Attachment Inhibitor, fostemsavir, GSK3684934, GSK-3684934, GSK 3684934
Description: BMS-663068, an oral, small molecule HIV attachment inhibitor (AI), is a prodrug for BMS-626529 which binds to the viral envelope glycoprotein gp120 and interferes with attachment of virus to the cellular CD4 receptor.
Bristol-Myers and ViiV
In December 2015, Bristol-Myers Squibb announced that it has entered into two individual agreements with ViiV Healthcare to divest its pipeline of investigational HIV medicines consisting of a number of programs at different stages of discovery, preclinical and clinical development. Under these agreements, ViiV will pay to Bristol-Myers Squibb upfront payments totaling $350 million with potential development and regulatory milestone payments of up to $518 million for the clinical assets and up to $587 million for the discovery and pre-clinical programs. Once products are approved and commercialized, ViiV Healthcare will pay tiered royalties. Additionally, ViiV Healthcare will pay sales-based milestone payments of up to $750 million for each of the clinical assets and up to $700 million for each of the discovery and pre-clinical programs. ViiV Healthcare will manage and resource the acquired development programs and Bristol-Myers Squibb will continue...See full deal structure in Biomedtracker
Partners: Pfizer Inc. Bristol-Myers Squibb Company
Additional information available to subscribers only: